clinical trial · NCT04770753
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
Non-Transfusion-dependent Alpha-ThalassemiaNon-Transfusion-dependent Beta-ThalassemiaPlacebo Matching MitapivatMitapivat
brief summary
The primary purpose of this study was to compare the effect of mitapivat versus placebo on hemolytic anemia in participants with alpha- or beta-non-transfusion dependent thalassemia (NTDT).
started
Dec 20, 2021
primary completion
Nov 13, 2023
completion
Dec 1, 2028
last updated
Apr 24, 2026
detailed description
The mitapivat group included 130 participants whereas the placebo group had 64 participants.
official title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol